BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 19837757)

  • 1. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
    Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
    J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors.
    Huang YE; Chen CF; Huang YJ; Konda SD; Appelbaum DE; Pu Y
    Acta Radiol; 2010 Sep; 51(7):782-8. PubMed ID: 20707663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?
    Biehl KJ; Kong FM; Dehdashti F; Jin JY; Mutic S; El Naqa I; Siegel BA; Bradley JD
    J Nucl Med; 2006 Nov; 47(11):1808-12. PubMed ID: 17079814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
    Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of 18-F FDG PET/CT in the pre-treatment evaluation of thymic epithelial neoplasms.
    Terzi A; Bertolaccini L; Rizzardi G; Luzzi L; Bianchi A; Campione A; Comino A; Biggi A
    Lung Cancer; 2011 Nov; 74(2):239-43. PubMed ID: 21439670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI.
    Kitajima K; Murakami K; Yamasaki E; Kaji Y; Sugimura K
    Ann Nucl Med; 2008 Jul; 22(6):505-12. PubMed ID: 18670857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing tumor response to therapy.
    Weber WA
    J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT.
    Groves AM; Win T; Screaton NJ; Berovic M; Endozo R; Booth H; Kayani I; Menezes LJ; Dickson JC; Ell PJ
    J Nucl Med; 2009 Apr; 50(4):538-45. PubMed ID: 19289428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.
    Troost EG; Bussink J; Hoffmann AL; Boerman OC; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 Jun; 51(6):866-74. PubMed ID: 20484426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Objective and subjective comparison of standard 2-D and fully 3-D reconstructed data on a PET/CT system.
    Strobel K; Rüdy M; Treyer V; Veit-Haibach P; Burger C; Hany TF
    Nucl Med Commun; 2007 Jul; 28(7):555-9. PubMed ID: 17538397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
    Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
    Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
    Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
    AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
    Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
    Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor volume assessment by 18F-FDG PET/CT in patients with oral cavity cancer with dental artifacts on CT or MR images.
    Baek CH; Chung MK; Son YI; Choi JY; Kim HJ; Yim YJ; Ko YH; Choi J; Cho JK; Jeong HS
    J Nucl Med; 2008 Sep; 49(9):1422-8. PubMed ID: 18703597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
    Ma BB; King A; Lo YM; Yau YY; Zee B; Hui EP; Leung SF; Mo F; Kam MK; Ahuja A; Kwan WH; Chan AT
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):714-20. PubMed ID: 17011447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.